News & Updates

Show Multimedia Only
Interval between biopsy and RARP does not impact biochemical recurrence in prostate cancer
Interval between biopsy and RARP does not impact biochemical recurrence in prostate cancer
28 Dec 2021
Venetoclax + chemo disappoints in double-hit lymphoma trial
Venetoclax + chemo disappoints in double-hit lymphoma trial
27 Dec 2021 byAudrey Abella

In patients with double-hit lymphoma (DHL), the addition of the BCL2 inhibitor venetoclax to a chemoimmunotherapeutic regimen comprising DA-EPOCH-R* led to excess treatment-related mortality compared with DA-EPOCH-R alone, according to the initial results of the phase II/III Alliance A051701 trial.

Venetoclax + chemo disappoints in double-hit lymphoma trial
27 Dec 2021